Generic CNS Drugs Embraces Biosimilar Development For Enhanced Treatment Options Is Playing A Role In Shaping The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Progress Between 2026 And 2030?
The market for ribonucleic acid (rna)-based oncolytic therapy has expanded swiftly in recent years. This market is anticipated to increase from $2.12 billion in 2025 to $2.51 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 18.7%. The historical expansion is a result of advancements in cancer virology research, a deeper understanding of tumor immunology, the presence of clinical trial infrastructure, heightened oncology research funding, and the initial successes observed in oncolytic virus studies.
The ribonucleic acid (rna)-based oncolytic therapy market is projected to experience significant expansion in the coming years. This market is anticipated to reach $4.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.4%. Factors contributing to this growth during the forecast period include a rise in approvals for rna-based cancer treatments, increased demand for tailored oncology solutions, an expanding range of immuno-oncology pipelines, heightened investment in gene and cell therapies, and innovations in rna delivery technologies. Key trends shaping the forecast period encompass ongoing advancements in rna virus engineering, a growing acceptance of combination oncolytic therapies, an intensified focus on activating the immune system, the broadening of targeted tumor-specific rna therapies, and improved integration of precision oncology tools.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28321&type=smp
Which Factors Are Influencing The Growth Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
The increasing integration of personalized medicine is projected to stimulate the expansion of the RNA-based oncolytic therapy market in the future. Personalized medicine involves healthcare solutions customized for unique genetic makeups, thereby enhancing effectiveness and minimizing negative side effects. The uptake of personalized medicine is on the rise, as a greater number of healthcare professionals and organizations acknowledge its capacity to improve patient results via focused treatments and accurate diagnostics. RNA-based oncolytic therapy holds significant importance in cancer treatment, as it aligns with the rising acceptance of personalized medicine to provide precise and individual-centric therapeutic strategies. As an illustration, during February 2024, the Personalized Medicine Coalition, a US-based organization advocating for customized medical treatments, reported that the FDA endorsed 16 novel personalized therapies for patients with rare diseases in 2023, an increase from 6 in 2022. Consequently, the expanding utilization of personalized medicine is a key factor propelling the RNA-based oncolytic therapy market.
How Is The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Categorized Across Its Segment Groups?
The ribonucleic acid (rna)-based oncolytic therapy market covered in this report is segmented –
1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations
3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents
What Trends Are Transforming The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
Key players in the ribonucleic acid (RNA)-based oncolytic therapy market are actively engaged in developing technological breakthroughs, such as synthetic messenger RNA (mRNA) technology. Their goal is to improve the efficiency of tumor targeting, enhance immune system activation, and achieve more accurate and long-lasting outcomes in cancer treatment. Synthetic messenger RNA (mRNA) technology is a biotechnology method that involves creating and delivering laboratory-produced mRNA sequences to instruct cells to produce specific therapeutic proteins, applicable for treating various diseases, including cancer. For example, in June 2024, CSPC Pharmaceutical Group Limited, a Chinese pharmaceutical company, obtained regulatory permission in China to begin clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This progress marks a substantial advancement within China’s messenger RNA therapeutics sector. SYS6020 leverages mRNA-lipid nanoparticle technology to precisely target and eliminate myeloma cancer cells with minimal negative effects, also showing potential for application in the treatment of specific autoimmune conditions.
Which Firms Are Influencing Competition In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
Get The Full Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report:
Which Region Accounts For The Largest Portion Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market 2026, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Oncolytic Virus Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report
Nucleic Acid Based Gene Therapy Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
